This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the risk/benefit ratio; (3) bridging the gap between multiple sclerosis and experimental autoimmune encephalitis; (4) promoting neuroprotection and repair; and (5) tailoring multiple sclerosis therapy to the individual patient. Each of these challenges will be discussed and placed in the context of current research into the pathogenesis and treatment of multiple sclerosis
Conferences traditionally play an important role in the ongoing medical education of healthcare prof...
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during p...
I n the management of patients with multiple sclerosis (MS), providers are all faced with thehighly ...
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düs...
This article is based on the ECTRIMS lecture given at the 25(th) ECTRIMS meeting which was held in D...
Multiple sclerosis (MS) is the commonest non-traumatic disabling disease to affect young adults. The...
Background: Multiple sclerosis (MS) is a chronic and autoimmune disease of the central nervous syste...
PURPOSE OF REVIEW Despite dramatic advances in the treatment of people with multiple sclerosis over ...
Multiple sclerosis (MS) is an immune system demyelinating and neurodegenerative disease of the centr...
For the past four decades, multiple sclerosis (MS) has been a focus for clinical trial development a...
The accelerating pace of technological and analytical development in the fields of genetic and pheno...
preventing the future: actively managing multiple sclerosis Michael Hutchinson Relapsing-remitting m...
Abstract: Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) and ...
Multiple sclerosis (MS) is the most frequent inflammatory and demyelinating disease of the Central N...
Every 5 minutes, someone somewhere in the world is diagnosed with an inflammatory, demyelinating, ne...
Conferences traditionally play an important role in the ongoing medical education of healthcare prof...
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during p...
I n the management of patients with multiple sclerosis (MS), providers are all faced with thehighly ...
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düs...
This article is based on the ECTRIMS lecture given at the 25(th) ECTRIMS meeting which was held in D...
Multiple sclerosis (MS) is the commonest non-traumatic disabling disease to affect young adults. The...
Background: Multiple sclerosis (MS) is a chronic and autoimmune disease of the central nervous syste...
PURPOSE OF REVIEW Despite dramatic advances in the treatment of people with multiple sclerosis over ...
Multiple sclerosis (MS) is an immune system demyelinating and neurodegenerative disease of the centr...
For the past four decades, multiple sclerosis (MS) has been a focus for clinical trial development a...
The accelerating pace of technological and analytical development in the fields of genetic and pheno...
preventing the future: actively managing multiple sclerosis Michael Hutchinson Relapsing-remitting m...
Abstract: Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) and ...
Multiple sclerosis (MS) is the most frequent inflammatory and demyelinating disease of the Central N...
Every 5 minutes, someone somewhere in the world is diagnosed with an inflammatory, demyelinating, ne...
Conferences traditionally play an important role in the ongoing medical education of healthcare prof...
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during p...
I n the management of patients with multiple sclerosis (MS), providers are all faced with thehighly ...